Q-omics provides the consensus-scored MIR8088 profile across patient tissues and cancer cell-line models. MIR8088 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR8088 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR8088 RNA expression shows 2,643 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where MIR8088 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8088 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8088 survival associations across molecular data types. MIR8088 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8088 RNA expression–survival associations across cancer types. High MIR8088 expression shows unfavorable associations in KIRC, LUSC, OV, BLCA, STAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR8088 RNA expression.
This table summarizes MIR8088 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8088. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8088 shows lower tumor expression in LUSC. The LUSC box plot shows higher MIR8088 RNA expression in normal versus tumor tissue (log2 FC = −0.124, t-test p = .011).
This table shows molecular features associated with MIR8088 in patient tissues and cancer cell lines. In patient samples, MIR8088 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
